Illustration: Gabriella Turrisi/Axios
Sanofi and privately held Kali Therapeutics signed a $1 billion-plus licensing deal to develop autoimmune disease treatments, the companies said Monday.
Why it matters: Sanofi has been an active biotech dealmaker as it seeks to become an immunology powerhouse.
